The development of Jiangsu Xiansheng Co., Ltd.

Break through the old model of drug marketing;

-1995, creating a "general distribution" model for pharmaceutical marketing enterprises in China.

—— The first company in China to provide all-round services such as product packaging design, advertising planning and terminal promotion for pharmaceutical manufacturers.

-The annual sales of the first "exclusive distribution" drug in China exceeded 300 million yuan.

Abandoning the old drug sales model, taking the lead in adopting the new "total distribution" model and achieving impressive results, which laid the foundation for the development of the voice and completed the original accumulation of the enterprise. Simcere successively acquired and controlled:

Jiangsu Hanhe Pharmaceutical Co., Ltd.

-Hainan Haifu Pharmaceutical Co., Ltd.

-Shanghai Haciyi Pharmaceutical Co., Ltd.

—— Nanjing Dongyuan Pharmaceutical Co., Ltd.

—— Yantai Maidejin Bioengineering Co., Ltd.

—— Jilin Boda Pharmaceutical Co., Ltd.

Nanjing Dongjie Pharmaceutical Co., Ltd.

Wuhu renzhong pharmacy co., ltd

Focusing on the M&A expansion of pharmaceutical production enterprises, simcere has surpassed the single business scope of pharmaceutical marketing, and its independent production capacity has ensured the independence of enterprises and greatly enhanced their ability to resist risks. On the basis of integrating R&D assets and teams of Jiangsu simcere New Drug Research Center, Hainan Chemical Medicine Engineering Technology Research Center and Jiangsu Pharmaceutical Industry Research Institute Co., Ltd., simcere established Jiangsu simcere Research Co., Ltd. in 2004. From June 2003 to February 2003, with the approval of the Ministry of Personnel, Xiansheng Technology established a postdoctoral research center, and in 2006, it established a "Joint Laboratory for Innovative Drugs" with Tsinghua University. At the end of 2006, a 5,000-square-meter drug research and development base was put into use at the eastern foot of Nanjing Zijin Mountain.

Establishing a drug research and development team and independent research and development capabilities constitute the core competitiveness of Xiansheng. Occupy the commanding heights of technology and constantly introduce new products with advantages, which ensures the sustainable development of Xiansheng and injects eternal vitality into the enterprise. 20 1 1 White House Station, New Jersey, USA, 201/news-Merck (NYSE:MRK, commonly known as Merck outside the United States and Canada) and China's simcere (NYSE:SCR) officially announced today.

The two partners announced the news at the signing ceremony held by Merck Research Institute in Ravi, New Jersey, USA. Chairman of the board of directors of Merck Co., Ltd. Ke Jiarui; History of President of Merck Global Human Health Department; Feng Naxi, President of Merck East China District; Ren Jinsheng, Chairman and CEO of Voice Group; And Dr. Zhang, President of Xiansheng Technology, attended the signing ceremony.

Member the Political Bureau of the Communist Party of China (CPC) Central Committee, Secretary jiangsu provincial party committee and Director of the Standing Committee of Jiangsu Provincial People's Congress Luo Zhijun attended the signing ceremony. This novel and creative way of cooperation will bring together the rich R&D and sales experience and resources of a multinational pharmaceutical company and a leading pharmaceutical company in China, so as to achieve the goal of establishing a strategic partnership between the two sides. The cooperation will include product research and development, registration, manufacturing and sales of both parties. In addition, in the initial stage of cooperation, we will focus on leading brand drugs in the field of cardiovascular and metabolic diseases.

According to the cooperation agreement between the two companies, the two companies will provide the joint venture company with their selected brands and generic drug combinations in the field of cardiovascular diseases, including Merck/Merck &; Reg (simvastatin), Kosuya &; Reg (losartan) and renitec &；; Reg from simcere (enalapril) and Cinta (amlodipine besylate) and Sufutan (rosuvastatin). At the same time, the two sides will actively cooperate to improve the accessibility of sitagliptin for diabetic patients in China. Sigliptin is an innovative DPP-4 inhibitor, which is used to treat type 2 diabetes. In China, the obvious public health threat caused by type 2 diabetes is increasing.

"Merck is honored to cooperate with the voice. Xiansheng is a leading pharmaceutical company in China. Merck and Xiansheng have the same mission, which is to promote the development of medical and health undertakings in China. " Shi said, "At the same time, cooperation is also an important step for Merck to expand its business strategy in China, which coincides with the goal of the China government to improve the accessibility of quality drugs." "Today's cooperation is another important milestone in Saisen's unremitting pursuit of improving patients' quality of life by providing innovative drugs. Ren Jinsheng said, "The purpose of this innovative cooperation is to meet the huge challenges of China's medical system and meet the needs of China patients and other medical stakeholders." "The cooperation between Xiansheng and Merck is not only of great strategic significance to both parties, but also a landmark event in the biopharmaceutical industry in Jiangsu Province. Luo Zhijun, secretary of jiangsu provincial party committee and director of the Standing Committee of the Provincial People's Congress, pointed out: "The biopharmaceutical industry is a strategic emerging industry that Jiangsu Province focuses on. The cooperation between Merck and Xiansheng will inject fresh impetus into the development of the whole industry and help Jiangsu to provide more high-quality drugs for China and the world. "

The establishment of a joint venture will depend on the finalization of the terms of cooperation between the two parties.

The vision of Vonaxi, president of Merck China, three months ago, instantly became a reality.

On July 22nd, Merck of the United States, the second largest pharmaceutical company in the world (called Merck outside the United States and Canada), signed a framework cooperation agreement with China Synthetic Apex Group and decided to establish a joint venture company in China. The two sides took out their selected brands and generic drug combinations and handed them over to the joint venture company for operation, thus achieving a major breakthrough in the cardiovascular and diabetes drug market. According to its three-year strategic plan, Merck will carry out a series of cooperation, acquisition and merger measures to improve its original marketing channels.

In September 2009, Feng Naxi, who just took over the China market for nine months, said in an interview with the media that for R&D company, the development speed of China market is faster than anywhere else. Among the most valuable markets in the world, China will become the third in three years and the largest vaccine market in the world by 2020.

Despite the high evaluation of China market, the development pace of Merck, which has been in China for 20 years, is not significant, which is due to its unsatisfactory channel promotion and high drug price.

In order to change this situation, Merck took the initiative to reduce the price of drugs for cardiovascular diseases to 20 10 by 52%, becoming the first foreign-funded original drug to enter the national list of essential drugs. Feng Naxi admits that this will greatly reduce profits, but in exchange for more coverage of medical institutions, especially grassroots community health centers. The planned joint venture will focus on generic drugs with relatively low prices, which will undoubtedly help Merck achieve wider coverage.

The courseware of Merck 20 10 shows that its business focus is to expand the use of products in primary medical institutions, especially for chronic diseases that need long-term use; Ensure the market access of products in every province and city, continue to speed up market development and multi-channel market education, so that products can be effectively distributed to the vast market; At the same time, explore the establishment of business partner cooperation mode to improve product coverage.

Feng Naxi said that in the next three years, Merck will continue to deepen the China market and expand its new business capabilities through three channels: First, strengthen its own business; Second, look for strategic partners; Third, mergers and acquisitions.

The cooperation with simcere is Merck's second development plan while strengthening its own business.

According to the data, simcere has a sales team of more than 800 people, more than 65,438+000 strategic partners and more than 65,438+0,500 distributors in China, and its products are marketed to more than 4,000 hospitals and 70,000 pharmacies. And these are exactly what Merck lacks.

Feng Naxi's development strategy for the next three years also includes the arrangement based on the unbalanced development between the eastern and western parts of China. "We have established ten regions according to the urban clusters in various regions of China, and established the regional general manager responsibility system respectively. It should be said that we are the first multinational pharmaceutical company to deploy nationwide. "

I'm afraid Feng Naxi can't just expect a simcere to make these ten regions play the expected role. In the future market breakthrough, he will make more use of M&A to achieve rapid scale expansion, so as to grasp the huge business opportunities created by China medical reform.

"China wants to establish a perfect medical and health security system, which is not available in other countries in the world. Medical reform in developing countries is usually to establish a preliminary medical system, while China has begun to establish a medical system that basically covers the whole country, especially the national essential drug system, with the aim of solving the accessibility of drugs, improving the coverage of medical insurance, and narrowing the differences in medical environment between the east and the west. " Feng Naxi said.

Like Merck, many multinational pharmaceutical giants have taken a fancy to the business opportunities of medical reform in China. It is conceivable that the competition will be more intense in the future. Whether Merck can change the long-term tepid situation depends on how brave it is to break through itself.

Merck is not the first multinational pharmaceutical company to establish a joint venture with a domestic pharmaceutical company. In June this year, Pfizer, the world's largest pharmaceutical company, signed a letter of intent with Haizheng Pharmaceutical Co., Ltd., and the two sides will jointly set up a joint venture company to realize the wider commercialization of related drugs through a global marketing platform. Before Pfizer, Novartis, another pharmaceutical giant, also announced the completion of the joint venture with China vaccine company Zhejiang Tianyuan Biopharmaceutical Co., Ltd.

Why do domestic pharmaceutical companies attract multinational pharmaceutical giants to establish joint ventures? Dai Haosen, a medical expert, told reporters that the most important purpose of cooperation between multinational pharmaceutical companies and China companies is to occupy a larger share in the China market. Because multinational pharmaceutical companies are in a leading position in technology and products, they are not as good as domestic enterprises in domestic market expansion and understanding of China policies. Moreover, cooperating with domestic enterprises in production and sales can reduce the cost of multinational pharmaceutical companies, and for domestic enterprises, they can also learn from foreign advanced technology and management experience.

At the same time, an industry insider said that in the past, if multinational pharmaceutical companies wanted to continue to grow and develop, most of them would adopt mergers and acquisitions, but there were not many good companies worth acquiring in the market, and they might not be able to acquire them. Therefore, large multinational pharmaceutical companies began to gradually replace "acquisition" with "investment".

The cooperation between Merck (called "Merck" outside the United States and Canada) and Xiansheng, which has received much attention before, is rapidly entering the practical level. "We hope to start cooperative sales on September 1 day to show our complementarity. Quick results are also an innovation of our cooperation. " Ren Jinsheng, Chairman and CEO of the Board of Directors of Voice Group, said excitedly at the press conference of Merck and Voice in August 16. At this meeting, the two sides revealed the contents of cooperation and more details of establishing a joint venture in China. In order to further strengthen disease classification management, evaluate the quality of diagnosis and treatment of rheumatism, and improve the level of diagnosis and treatment of rheumatism in China, the National Data Center for Diagnosis and Treatment of Rheumatism (CRIS Center for short) was established in Beijing on 201165438+1October 27th. Leaders of the Department of Medical Management of the Ministry of Health, members of the Rheumatology Branch of the Chinese Medical Association, and 42 professional rheumatologists from all over the country attended the kick-off meeting of CRIS Center. At the kick-off meeting of CRIS Center, Simcere held a satellite meeting of Aidixin, a new national rheumatoid drug. The satellite conference was presided over by Professor Zeng Xiaofeng, Chairman-designate of China Rheumatology Branch. At the meeting, Professor Li Xiaofeng from the Second Affiliated Hospital of Shanxi Medical University made a full discussion on the time to market, product information, advantages, etc. Through this satellite meeting, experts from the Department of Rheumatology of the National 142 Key Hospital clearly and in detail learned the news of the upcoming listing of Adelson and the information of its core products. At the same time, simcere took this opportunity to establish a good communication and cooperation mechanism with rheumatologists all over the country, which laid a very important foundation for Aidexin, which will be listed in the whole country.

Edexin is the first ilamod preparation listed in the world, and it is also a brand-new structural type of DMARDS. Its main indication is active rheumatoid arthritis, which can significantly improve the disease symptoms and inflammatory indicators of patients with rheumatoid arthritis and relieve their pain. On August 24th, 20 1 1, the voice announced that Edxin (Erasmus tablets) had been officially awarded the national first-class new drug certificate and drug registration approval issued by SFDA of China. Edson will be listed nationwide on June 20 12.

2065438+02108 12 simcere held a press conference on the industrialization achievements of Elamod, a major scientific and technological special support project of "major new drug creation", and officially announced the list of REG, the world's first small molecule drug for treating rheumatoid arthritis. The meeting was presided over by Rui Chenggang, a famous mouth of CCTV. Professor Li, Chairman of Rheumatology Branch of Chinese Medical Association, Professor Bao Chunde, Vice Chairman of Rheumatology Branch of Chinese Medical Association, Academician of China Academy of Engineering, Professor Liu Changxiao, Researcher of Tianjin Institute of Medicine, and Li Zhengqing, President of China District of Merck attended the meeting and delivered speeches respectively. Professor Li introduced the current situation and limitations of drugs for treating rheumatoid diseases to rheumatologists from all over the country and journalists from more than 40 famous public or medical and financial media in China. Professor Bao Chunde introduced the mechanism of Addison & reg and the results of clinical research. Subsequently, Professor Li and Professor Bao Chunde also attended the press conference together with Ren Jinsheng, Chairman of Xiansheng Technology, and Yin Xiaojin, Senior Vice President, and answered questions from reporters. Dozens of reporters from the national media talked about Addison &; Reg gave detailed answers to enthusiastic questions about R&D process, medication plan, clinical value, possible future indications expansion, overseas expansion plan and so on. Ren Jinsheng, chairman of the voice group, said: Addison &; Reg provides a new and more effective treatment method for clinicians in China. The voice has always been to seek more effective drugs for patients through continuous innovation, so a new class of drugs, Addison &; Reg, its listing is also a major breakthrough in the road of drug innovation. Professor Li said: Addison developed; Reg is the first preparation of Elamod in the world and the first new anti-rheumatoid drug with independent intellectual property rights in China. Edison company. The successful development and marketing of the drug is of great significance to the treatment and control of rheumatic diseases, and it is an important milestone in the scientific research work of preventing and treating rheumatic diseases in China, which indicates that China has been in a leading position in the research and development of anti-rheumatic drugs. Rheumatoid arthritis is one of the biggest diseases in the world. At present, the main products in the world are used to treat symptoms, and there is still a lack of ideal drugs for small-molecule autoimmune diseases. 20 1 1 August, Addison &; Reg China State Food and Drug Administration (SFDA) officially obtained the national first-class certificate of new drugs and the approval of drug registration, which really filled this gap. Treating the pathogenesis of rheumatoid arthritis will bring health protection to hundreds of millions of patients.

You can see the great value brought by innovation, but you may not understand the heavy price of innovation. On the road of drug innovation, pay and gain are not completely proportional. Fortunately, this time, Xiansheng can have a celebration dinner. R&D team in the field of science and technology 19, basic and clinical research experts 150, 12,1500,000 RMB. With these figures, simcere finally created the world's first small molecule drug for the treatment of rheumatoid arthritis-"Aidimo". 20 12 18, ren jinsheng, chairman of the board of directors of voice group, announced in Beijing that "Addison" was officially listed for clinical use. Edxin is a small molecule anti-rheumatoid arthritis drug with completely independent intellectual property rights in China, and it is also the first small molecule drug in the field of rheumatoid arthritis treatment since 17.

Develop tortoise-rabbit race

20 1 1 In August, the news broadcast broadcast the news that Addison, who had taken the lead in research and development, officially obtained the SFDA national first-class new drug certificate and drug registration approval. This news, which lasted only a few seconds, attracted millions of people to call Xiansheng through CCTV to ask when the drug could be bought in the market. The market demand is so urgent. According to Li, chairman of the Rheumatology Branch of the Chinese Medical Association and director of the Rheumatology Immunology Department of Peking University People's Hospital, this is indeed a real clinical reaction. In 2006, when Jia made a survey in China, he found that among the diseases that caused physical disability, the one with the highest disability rate was cerebrovascular disease, and the other was arthropathy. However, only 44% of these patients received standardized treatment, and nearly 56% of them did not receive good treatment or did not receive anti-rheumatic treatment at all, which eventually led to disability. The main reason for this situation is that many people, including doctors, have always believed that rheumatoid arthritis is incurable. Methotrexate, the first-line drug for the treatment of rheumatoid arthritis in clinic, is actually "not worthy of the name" because it is actually an anti-tumor drug. Elamod first entered simcere's field of vision in 2004, when Ding Lei, who had been exploring simcere's synthesis technology room for five years, searched for another first imitation drug registration in the evaluation center of the State Food and Drug Administration, by the way, he entered the English name Elamod, inquired about China's application, and suddenly found that Tianjin Institute of Medicine had applied for evaluation of new drugs according to 1. 1. A week later, Yin Xiaojin, vice president of Xiansheng R&D, appeared in the office of the president of Tianjin Pharmaceutical Research Institute. Soon, a technology transfer agreement was signed, and the voice began to jointly develop Elamod with Tianjin Institute of Medicine. At that time, Japan was one of the leaders in this field. Just compared with Vanguard, the research directions of the two sides are slightly different, and it was impossible to judge who was right or wrong at that time. After a series of in-depth research and comparison, the R&D team has a sense of pride in "racing" with international leading enterprises in simcere. "It was a game that was far better than ours. This is a very exciting and risky competition. " Li, project director of Simcel Addison, said. Since then, in the R&D competition similar to the tortoise and rabbit race, what Xiansheng has done is to make unremitting efforts to shorten the gap with international counterparts. At the same time of drug research, the clinical team is also screening clinical research hospitals. On June 5438- 10, 2004, Elamod started the second phase of clinical research, with Shanghai Renji Hospital as the team leader. At first, Bao Chunde, director of Rheumatology Department of Renji Hospital affiliated to Shanghai Second Medical University, designed a clinical research scheme for fresh students and compared it with placebo. This design caused some controversy from the beginning. However, Bao Chunde insisted that according to foreign experience, a brand-new drug should be compared with placebo first, and using ordinary positive drugs as control may not necessarily produce effective results. Elamod is a new drug that has never been listed in the world. As a researcher, he must first convince himself that this drug is effective for rheumatoid disease. What makes Bao Chunde feel gratified is that the management and researchers of Pioneer also have a scientific vision and are willing to take risks. Finally, six hospitals participated in the second phase clinical study of Elamod, and 288 patients were selected. The final result proves that Elamod can effectively treat rheumatoid arthritis. According to the clinical research report published in Japan, the control drug used in the third phase of clinical practice is sulfadiazine tablets. Bao Chunde decided to use the "gold standard" methotrexate tablets for the treatment of rheumatoid arthritis as a control drug according to the 2002 edition of the guidelines for the treatment of rheumatoid arthritis issued by the American Rheumatology Association. At this point, the simcere team thinks that it has found a way to surpass its Japanese counterparts.

Innovation is the reason for existence.

The results of the third phase clinical study excited everyone. Studies have shown that ilamod can take effect within 4 ~ 6 weeks at the earliest, can inhibit the expression of various cytokines and rheumatoid factors, obviously improve the symptoms and signs of patients with rheumatoid arthritis, and improve the quality of life of patients, and is safer than the traditional cytotoxic drug methotrexate. More importantly, as the only drug that can promote osteoblast differentiation, Elamod can effectively prevent bone destruction and reduce the disability rate and teratogenesis rate of patients. In addition, animal experiments using Elamod and methotrexate at the same time further show that they have a certain synergistic effect. Bao Chunde believes that the above conclusions undoubtedly suggest that ilamod will be a new therapeutic drug for rheumatoid arthritis. It is reported that with the support of major national science and technology projects, Xiansheng has also started the fourth phase of clinical research on Edxin after completing the preparation for listing. "We want to observe the clinical safety and effectiveness of more than 2,000 patients and design a long-term clinical trial with an observation period of one year. We hope to recruit 900 patients, deeply explore the new indications of Elamod, and deeply study the synergistic mechanism with other anti-rheumatic drugs. " Yin Xiaojin said. Ren Jinsheng, chairman of simcere, gave Ira Maud a trade name: Edxin. Originally, some people suggested using innovative "new" and others suggested using thriving "new", but Ren Jinsheng chose the word "new". It is simple, vivid and accurate to describe the long road of R&D in 12 years with hard, spicy and hard. Ren Jinsheng said. "